NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ
Post# of 73
(Total Views: 254)
Posted On: 12/29/2021 3:15:39 PM
NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to create wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. “The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and prediabetes manage their glucose levels,” reads a recent article. “The company has recently followed up with the release of the MiBoKo application. This service, which has been in development for the past 18 months, seeks to address a significant mass-market opportunity, which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores, which are based on glucose tolerance or insulin resistance. Prediabetic patients, those facing obesity concerns, or individuals looking to monitor their glucose intake would all benefit from this application.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to create wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. “The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and prediabetes manage their glucose levels,” reads a recent article. “The company has recently followed up with the release of the MiBoKo application. This service, which has been in development for the past 18 months, seeks to address a significant mass-market opportunity, which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores, which are based on glucose tolerance or insulin resistance. Prediabetic patients, those facing obesity concerns, or individuals looking to monitor their glucose intake would all benefit from this application.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Nemaura Medical Inc. (NMRD) Stock Research Links
Scroll down for more posts ▼